JNJ · News · 20260817N
Revenue Performance and Mix
JOHNSON & JOHNSON · 2026-08-17 · Importance 30 · Surprise 40
Johnson & Johnson exceeded quarterly revenue and earnings expectations while maintaining its 2026 EPS guidance. STELARA biosimilar competition continued to weigh on reported growth in the immunology business. Revenue excluding STELARA was described as growing at a double-digit rate, indicating a favorable underlying mix shift. MedTech cardiovascular performance remained a relative soft spot, while the broader outlook stayed positive.